đź’Š

Hypertension Medication Overview

Jun 24, 2025

Overview

This lecture provides a concise review of hypertension medication classes, their key characteristics, how to select agents based on individual factors, and important prescribing tips.

Major Antihypertensive Drug Classes

  • Four main first-line classes: thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers (CCBs).
  • Beta blockers are not considered first-line unless specific indications exist; other agents are used as fourth or fifth-line options.
  • All four main classes are roughly equally effective in lowering blood pressure, but patient response varies.

Drug Selection Criteria

  • Initiate monotherapy with one first-line class; beta blockers not usually first-line except for specific conditions.
  • Age: Patients <50 years typically respond better to ACE inhibitors or ARBs.
  • Race: Black patients respond best to thiazide diuretics or long-acting CCBs; all classes are options for Caucasian patients.
  • Combine CCB with ACE inhibitor or ARB if monotherapy insufficient in black patients.

Comorbid Conditions Influencing Drug Choice

  • BPH: Use alpha blocker
  • Essential tremor: Use beta blocker
  • Hyperthyroidism: Use beta blocker
  • Migraine: Use beta blocker or CCB
  • Osteoporosis: Use thiazide diuretic
  • Raynaud’s: Use CCB
  • Atrial fibrillation/flutter: Use beta blocker or CCB
  • Post-MI: Use ACE inhibitor, ARB, beta blocker, or aldosterone antagonist

Contraindications and Drug Avoidance

  • Do not use ACE inhibitor in angioedema or during pregnancy.
  • Avoid non-selective beta blockers in bronchospastic disease.
  • Avoid methyldopa in liver disease.
  • Avoid certain drugs in specific conditions: beta blockers/central alpha 2 agonists (depression), thiazides/loops (gout), ACE/ARB/renin inhibitors/aldosterone antagonists (hyperkalemia), thiazides (hyponatremia), ACE/ARB/renin inhibitors (renal vascular disease).
  • Avoid ACE inhibitors and ARBs together in combination therapy.

Approaches When Monotherapy Fails

  • If no response to initial drug, either increase dose (prefer one-step increase) or change drug class after 4-6 weeks.
  • Most blood pressure response occurs at lower-to-moderate doses; increasing dose yields diminishing returns and more side effects.
  • Two or three drugs at half-standard dose may be more effective and cause fewer side effects than high-dose monotherapy.

Drug Class Overviews & Side Effects

  • Calcium Channel Blockers: Two types—dihydropyridine (prefer for hypertension, ex: amlodipine, procardia), non-dihydropyridine (affect heart, ex: verapamil, diltiazem). Side effects: dihydropyridine—edema, headache; non-dihydropyridine—constipation.
  • ACE Inhibitors: Block conversion of angiotensin I to II, lowering BP. Side effects: cough, hyperkalemia, reduced GFR, hypotension.
  • ARBs: Block angiotensin II receptors; similar effects/side effects as ACE inhibitors but less cough.
  • Thiazide Diuretics: Cause volume loss, effective in elderly/black patients. Side effects: electrolyte imbalances, hyperglycemia, hyperuricemia.
  • Beta Blockers: Lower HR and BP by blocking adrenergic receptors. Side effects: dizziness, fatigue, cold extremities, GI issues.

Additional Prescribing Tips

  • Take antihypertensive meds in the morning due to lower nocturnal blood pressure.

Key Terms & Definitions

  • Thiazide Diuretic — increases urine output by affecting kidney tubules, lowering blood volume.
  • ACE inhibitor — blocks angiotensin-converting enzyme, reducing blood vessel constriction.
  • ARB (Angiotensin Receptor Blocker) — prevents angiotensin II from tightening blood vessels.
  • Calcium Channel Blocker (CCB) — inhibits calcium entry into heart/vessel cells, causing relaxation.
  • Beta Blocker — reduces heart rate and output by blocking beta-adrenergic receptors.

Action Items / Next Steps

  • Review drug dose ranges and side effect profiles for each antihypertensive class.
  • Apply patient-specific factors (age, race, comorbidities) when selecting antihypertensive therapy.
  • Avoid contraindicated drugs in at-risk patient groups.